Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$62.73K$62.73K+388.0% vs Q2 2018 Net Income-$7.84M-$7.84MN/M vs Q2 2018 EPS Diluted-$13.57-$13.57— vs Q2 2018 Gross Profit$33,156+169.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$687,623N/M Margins · derivedGross margin52.9%−42.9 pt vs Q2 2018
Operating margin-1554.0%+4799.3 pt vs Q2 2018
Net margin-12494.3%−2763.2 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 13, 2019 · 44 d after period end